

## Patent Application Attorney Docket No.PC24974A

Iful

	certify that this correspondence is being deposited as first class mail with sufficient postage and is addressed to: Commissioner for
Patents, P	P.O. Box 1450, Alexandria, VA 22313-1450 of tills [1] th day of October 2005.
	/ 1//
Ву	William III
_	(Signature of person mailing)
	/A. David Joran
	(Typed or pented name of person)
	Copper Community

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Erik Ho Fong Wong

APPLICATION NO.: 10/602,447 : Examiner:

FILING DATE: June 24, 2003 : Group Art Unit: 1614

TITLE: METHOD OF PROMOTING SMOKING:

CESSATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA. 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted

Date: October 17, 2004

A. David Joran

Registration No. 37,858 Attorney for Applicants

Pfizer, Inc.
Patent Department
150 East 42<sup>nd</sup> Street
New York, NY 10017
(212) 733-3381

OTPE 420 OCT 2 0 2005

INFORMATION DISCLOSE E CITATION							ATTY. DOCKET NO. 24974A							SERIAL NO. 10/602,447				
(Use several sheets if necessary)							APPLICANT Erik Fo Hong Wong											
	FIL	FILING DATE June 24, 2003							GROUP 1614									
						U.S.	PATEN	NT D	OC	UME	ENTS	<del>, -</del>						
EXAMINER INITIAL		- 10	DOCUMENT NUMBER								DATE	NAME		CLASS	SUBCLASS	FILING IF APPROP	DATE RIATE	
	0	2	0	0	1	3	3	1		2	31-Jan-02	J. Schildk	raut					
										,								
										•								
					FC	REIG	N PAT	[EN	T DC	ocu	IMENTS	•		<del>'</del>		<del></del>		
DOCUMENT NUMBER										DATE	COUNTRY		CLASS	SUBCLASS	TRANSL	ATION		
										+						YES	NO	
•	0	0	0	5	9	4	8	$\dashv$	6		12-Oct-00	wo						
							ļ	+		+								
			l		<u> </u>	•	<u> </u>											
		1	OTHE	R DOCL	MENTS	(Incl	uding A	Autho	or, T	itle,	Date, Perti	nent Page	es, E	tc.)				
		Harkir depre	Harkin A. et al., "Activity and onset of action of reboxetine and effects of combination of sertraline in an animal model of depression", Europ. J. of Pharmacology, Vol. 365, 1999, pps. 123-132															
		Harkir NMDA	Harkin A. et al., "Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and β1-adrenergic receptors in an animal model of depression", <u>J. Neural Transmission</u> , Vol 107, 2000, pps. 1213-1227															
			Ferri M. et al., "Sertraline and reboxetine association in depressive pseudodementia: good cardiovascular effects", Arch. Gerontol. Geratrics, Suppl. 7 2001 pps 121-125															
	-	Demitrack, M.A., "Can Monoamine-Based Therapies Be Improved?", J. Clinical Psychiatry Vol. 63, 2002																
	+														<del></del>			
EXAMINER							DATE CONSIDERED .											
EXAMINER: I with next com	Initial if re	eference con on to applica	sidered, who	ether or not ci	tation is in co	nformance	with MPER	P 609;	Draw li	ne thr	ough citation if not i	n conformance	and not	considered.	Include copy of	this form	n	

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE